Evidence map›Paper›PMID 40103284›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

The Super Enhancer-Driven Long Noncoding RNA PRKCQ-AS1 Promotes Neuroblastoma Tumorigenesis by Interacting With MSI2 Protein and Is Targetable by Small Molecule Compounds.

Sujanna Mondal, Pei Y Liu, Janith Seneviratne, Antoine De Weck, Pooja Venkat, Chelsea Mayoh, Jing Wu, Jesper Maag, Jingwei Chen, Matthew Wong and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Targeting the BMX in cancer: molecular mechanisms and emerging therapeutic strategies.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sujanna MondalChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Pei Y LiuChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Janith SeneviratneChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Antoine De WeckChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Pooja VenkatChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Chelsea MayohChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Jing WuChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Jesper MaagGarvan Institute of Medical Research, Genome Informatics, Genomics & Epigenetics Division, 384 Victoria St., Darlinghurst, NSW, 2010, Australia.
Jingwei ChenChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Matthew WongChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Nenad BartonicekGarvan Institute of Medical Research, Genome Informatics, Genomics & Epigenetics Division, 384 Victoria St., Darlinghurst, NSW, 2010, Australia.
Poh KhooChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Lei JinSchool of Medicine and Public Health, University of Newcastle, Callaghan, NSW, 2308, Australia.
Louise E LudlowMurdoch Children's Research Institute, The Royal Children's Hospital & Department of Paediatrics, University of Melbourne, Melbourne, Australia.
David S ZieglerChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Toby TrahairChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Pieter MestdaghCenter for Medical Genetics Ghent, Ghent University, Ghent, Belgium.
Belamy B CheungChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Jinyan LiShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Marcel E DingerSchool of Life and Environmental Sciences, Faculty of Science, The University of Sydney, Sydney, NSW, Australia.
Ian StreetChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Xu D ZhangTranslational Research Institute, Henan Provincial People's Hospital, Tianjian Laboratory of Advanced Biomedical Science, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Glenn M MarshallChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.
Tao LiuChildren's Cancer Institute Australia and UNSW Centre for Childhood Cancer Research, University of New South Wales, Sydney, NSW, 2052, Australia.ORCID https://orcid.org/0000-0001-6244-7316

Funding

National Health and Medical Research CouncilNeuroblastoma AustraliaU.S. Department of Defense RA200308U.S. Department of Defense RA220088
6 · The paper itself

Abstract

Tumorigenic drivers of MYCN gene nonamplified neuroblastoma remain largely uncharacterized. Long noncoding RNAs (lncRNAs) regulate tumorigenesis, however, there is little literature on therapeutic targeting of lncRNAs with small molecule compounds. Here PRKCQ-AS1 is identified as the lncRNA most overexpressed in MYCN nonamplified, compared with MYCN-amplified, neuroblastoma cell lines. PRKCQ-AS1 expression is controlled by super-enhancers, and PRKCQ-AS1 RNA bound to MSI2 protein. RNA immunoprecipitation and sequencing identified BMX mRNA as the transcript most significantly disrupted from binding to MSI2 protein, after PRKCQ-AS1 knockdown. PRKCQ-AS1 or MSI2 knockdown reduces, while its overexpression enhances, BMX mRNA stability and expression, ERK protein phosphorylation and MYCN nonamplified neuroblastoma cell proliferation. PRKCQ-AS1 knockdown significantly suppresses neuroblastoma progression in mice. In human neuroblastoma tissues, high levels of PRKCQ-AS1 and MSI2 expression correlate with poor patient outcomes, independent of current prognostic markers. AlphaScreen of a compound library identifies NSC617570 as an efficient inhibitor of PRKCQ-AS1 RNA and MSI2 protein interaction, and NSC617570 reduces BMX expression, ERK protein phosphorylation, neuroblastoma cell proliferation in vitro and tumor progression in mice. The study demonstrates that PRKCQ-AS1 RNA interacts with MSI2 protein to induce neuroblastoma tumorigenesis, and that targeting PRKCQ-AS1 and MSI2 interaction with small molecule compounds is an effective anticancer strategy.

Indexed as

CarcinogenesisNeuroblastomaRNA-Binding ProteinsRNA, Long NoncodingAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceN-Myc Proto-Oncogene ProteinSuper EnhancersMSI2 protein, humanN-Myc Proto-Oncogene ProteinRNA-Binding ProteinsRNA, Long Noncodinglong noncoding RNAlong noncoding RNA inhibitorNeuroblastomaRNA binding proteinsmall molecule compoundstumorigenesis

Identifiers

PMID40103284
PMCPMC12079515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.